FGFR2 and neoplasm: Similarly, in a single arm phase II trial, patients with tumours overexpressing FGFR2 assessed by immunohistochemistry (13%) had a prolonged median PFS (8.5 vs. 5.6 months; p = 0.050), a higher response rate (87% vs. 69.5%), and a trend towards a prolonged overall survival (13.2 vs. 11.4 months; p = 0.055) [76].